TREATMENT OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES RECEIVING AZACITIDINE WHO ARE ENROLLED IN AVIDA, A LONGITUDINAL PATIENT REGISTRY

被引：0
|
作者：
Grinblatt, L. [1 ]
Narang, X.
Malone, M. [2 ]
Sweet, A. [3 ]
Dunne, S. [3 ]
Sullivan, A. [3 ]
机构：
[1] NorthShore Univ HealthSyst, Evanston, IL USA
[2] Oncol Hematol Med Associates Cent Coast, San Luis Obispo, CA USA
[3] Celgene Corp, Summit, NJ USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1345
引用
收藏
页码：531 / 531
页数：1
相关论文
共 50 条
  • [1] Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry
    Grinblatt, Davld L.
    Narang, Mohit
    Malone, James M., III
    Sweet, David A.
    Dunne, Tim S.
    Sullivan, Kristen A.
    [J]. BLOOD, 2008, 112 (11) : 581 - 581
  • [2] Patients with secondary myelodysplastic syndromes (MDS) who are enrolled in AVIDA, a longitudinal registry for patients receiving azacitidine (AZA)
    Grinblatt, D. L.
    Narang, M.
    Malone, J. M., III
    Sweet, D. A.
    Dunne, T. S.
    Sullivan, K. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Transfusion Independence in Patients with Hematologic Disorders Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry
    Grinblatt, Davd L.
    Narang, Mohit
    Malone, James M., III
    Sweet, David A.
    Dunne, Tim S.
    Sullivan, Kristen A.
    [J]. BLOOD, 2008, 112 (11) : 927 - 928
  • [4] Patients with hematologic disorders receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry, achieve transfusion independence
    Grinblatt, D.
    Narang, M.
    Malone, J.
    Sweet, D.
    Dunne, T.
    Sullivan, K.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S129 - S130
  • [5] Therapeutic Response to Azacitidine (AZA) In Patients With Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry
    Sekeres, Mikkael A.
    Narang, Mohit
    Komrokji, Rami S.
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Street, Thomas K.
    Swern, Arlene S.
    Sullivan, Kristen A.
    Grinblatt, David L.
    [J]. BLOOD, 2010, 116 (21) : 1207 - 1208
  • [6] Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry
    Grinblatt, David L.
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Swern, Arlene S.
    Sullivan, Kristen A.
    Narang, Mohit
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 887 - 895
  • [7] USAGE PATTERNS AND TRANSFUSION REQUIREMENTS IN PATIENTS ENROLLED IN AVIDA, A LONGITUDINAL REGISTRY OF PATIENTS WITH HEMATOLOGIC DISORDERS RECEIVING AZACITIDINE
    Grinblatt, L.
    Narang, X.
    Malone, M.
    Sweet, A.
    Dunne, S.
    Sullivan, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 281 - 281
  • [8] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [9] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
  • [10] Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
    T Bernal
    P Martínez-Camblor
    J Sánchez-García
    R de Paz
    E Luño
    B Nomdedeu
    M T Ardanaz
    C Pedro
    M L Amigo
    B Xicoy
    C del Cañizo
    M Tormo
    J Bargay
    D Valcárcel
    S Brunet
    L Benlloch
    G Sanz
    [J]. Leukemia, 2015, 29 : 1875 - 1881
12345